HENDERSON, Nev. - VolitionRx Limited (NYSE AMERICAN: VNRX), an epigenetics company specializing in diagnostics, announced the appointment of Dr. Andrew Retter as Chief Medical Officer (CMO), starting April 1, 2024. Dr. Retter will lead medical initiatives at Volition, ensuring that the company's scientific and clinical efforts are oriented towards patient needs.
Dr. Retter is an accomplished Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust in London. Since 2014, he has held a consultant position and leads Clinical Governance in Critical Care. His expertise lies in managing severe respiratory failure, ECMO, and thrombosis, and he is the only UK consultant dual-registered in Intensive Care and Haematology. Dr. Retter provides national guidance on complex haematology patients in critical care settings.
Since January 2022, Dr. Retter has advised Volition on the development and clinical utility of its Nu.Q® NETs test, a CE-marked routine blood test that detects diseases associated with NETosis, such as sepsis.
Cameron Reynolds, President and CEO of Volition, expressed enthusiasm about Dr. Retter's appointment, highlighting his expertise in Intensive Care Medicine and Haematology as crucial to Volition's success. Dr. Retter's role will focus on aligning research, development, and commercialization activities with patient care.
In response to his new role, Dr. Retter shared his belief in Volition's potential to revolutionize healthcare with its innovative diagnostic solutions. He emphasized the importance of early disease detection, rapid patient treatment, and monitoring treatment response in healthcare. Dr. Retter is confident in Volition's technology to significantly enhance patient outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.